With the recent approval of potential blockbuster lupus drug Benlysta, Human Genome Sciences ($HGSI) is on track to generate 'meaningful' revenue for the first time in its almost 20-year history. It has to share sales of the drug with marketing partner GlaxoSmithKline, explains Motley Fool scribe Brian Orelli, and will continue spending hundreds of millions on ramping up its sales force and supporting further R&D of the drug. Orelli expects the developer to actually begin showing a profit in 2013. Article